A five-residue secretagogue and a 44-residue releasing-factor analogue sit in the same catalogue aisle but different literatures. Research use only.
At a glance
Ipamorelin and tesamorelin are both catalogued under growth-hormone-axis research, which is where the resemblance ends. One is a five-residue synthetic pentapeptide amide built from non-standard amino acids; the other is a 44-residue analogue of a native releasing factor carrying a fatty acyl modification. They differ by an order of magnitude in molecular mass, they belong to different pharmacological classes, and the published literature behind them was generated in entirely different settings. All compounds discussed are supplied strictly as laboratory research materials. They are not for human or veterinary use, and nothing here is medical advice.
- Size and identity. Ipamorelin is Aib-His-D-2-Nal-D-Phe-Lys-NH2, CAS 170851-70-4, C38H49N9O5, 711.90 g/mol. Tesamorelin is a 44-residue GHRH(1-44) analogue bearing an N-terminal trans-3-hexenoyl group, CAS 218949-48-5, C221H366N72O67S, 5136.00 g/mol.
- Class. Ipamorelin is described in the primary literature as a growth hormone secretagogue. Tesamorelin is described as a growth hormone releasing factor analogue.
- Origin of the sequence. Ipamorelin is fully synthetic and contains residues that do not occur in translated protein, including aminoisobutyric acid and two D-configured aromatic residues. Tesamorelin follows a native human sequence with a chemical modification added at the N-terminus.
- Literature setting. Ipamorelin has a named animal and pituitary-cell characterisation. Tesamorelin's published record is predominantly clinical, which places most of it outside what a research-materials catalogue can discuss.
- How each is supplied. Both as lyophilised powder in a sealed vial with a lot-specific certificate of analysis.
What ipamorelin is
Ipamorelin is a pentapeptide amide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, catalogued under CAS 170851-70-4 with the molecular formula C38H49N9O5 and a mass of 711.90 g/mol. Three of its five positions are unusual. Aminoisobutyric acid is a quaternary residue that constrains backbone conformation, and both D-2-naphthylalanine and D-phenylalanine are D-configured, which places them outside the recognition window of most mammalian proteases. The C-terminal amide removes the free carboxylate. Every one of those choices is a synthetic design decision aimed at conformational rigidity and protease resistance, and together they make ipamorelin a small molecule by peptide standards rather than a fragment of anything endogenous.
The primary characterisation report describes it as the first selective growth hormone secretagogue (PMID 9849822). In rat pituitary cell cultures and in anaesthetised rats, growth hormone release was the measured variable, and the selectivity claim in the title rests on measuring other pituitary hormones in the same models rather than on growth hormone alone. That distinction is the substance of the paper: selectivity is an experimental result about which analytes moved and which did not in a defined animal and cell system.
For handling, the D-residues and the naphthyl side chain matter analytically. Naphthylalanine has a strong ultraviolet absorbance that dominates a chromatogram, and D-amino acid content is not resolved by a standard reversed-phase run at all, which is why epimeric impurity is a question for the certificate rather than for the eye. The catalogue entries are the ipamorelin research guide and ipamorelin.
What tesamorelin is
Tesamorelin is a 44-residue analogue of growth hormone releasing hormone (1-44) carrying an N-terminal trans-3-hexenoyl group, catalogued under CAS 218949-48-5 with the molecular formula C221H366N72O67S and a mass of 5136.00 g/mol. The single sulfur in that formula reflects one methionine in the sequence, which is the main oxidation-sensitive site in the molecule and a standing consideration for anyone assessing lot stability. At more than five kilodaltons it sits near the practical ceiling of solid-phase synthesis, and its purity profile behaves accordingly: the impurity population in a long peptide is dominated by deletion sequences and truncated chains rather than by a handful of discrete side products. The interpretation of a purity figure at that chain length is discussed in what 99 percent peptide purity means.
Its published literature is a different kind of literature. Both catalogued reviews are drug-development profiles of a growth hormone releasing factor analogue (PMID 19243281, PMID 21283099). Clinical literature exists for tesamorelin in HIV-associated lipodystrophy, and it is outside the scope of a research-materials catalogue. No results from that literature are reproduced here, and none should be inferred from the fact that the citations are listed. What the reviews establish for a bench user is narrow and useful: the compound's structural class, the hexenoyl modification, and its identity as a full-length releasing-factor analogue rather than a fragment.
The catalogue entries are the tesamorelin research guide and tesamorelin, filed with other cellular research materials.
Where the research models differ
Preclinical characterisation versus clinical profile
The asymmetry between these two is the most important thing to understand before designing an experiment. Ipamorelin has an accessible preclinical anchor: a named rodent and pituitary-cell characterisation with defined measured hormones (PMID 9849822). Tesamorelin's catalogued record is clinical review material. An investigator looking for a rodent baseline to compare against will find one readily for ipamorelin and will need to go outside these citations for tesamorelin.
Molecular scale changes the assay
A 711.90 g/mol pentapeptide and a 5136.00 g/mol 44-mer are not handled by the same analytical methods at the same settings. Column chemistry, gradient, and mass spectrometry charge-state envelopes all differ. Weighing error is also proportionally different: at fixed balance precision, the molar error on a small peptide is much larger than intuition suggests, which is one argument for calculating concentrations rather than estimating them, using the reconstitution calculator.
Different stability liabilities
Tesamorelin's methionine gives it a defined oxidation site, and its length gives it more amide bonds available for hydrolysis. Ipamorelin's D-residues and constrained backbone make it the more protease-resistant of the two by design, though protease resistance says nothing about resistance to simple aqueous hydrolysis in a vial on a bench.
What a certificate has to prove
For ipamorelin, the certificate has to establish that the correct stereochemistry and the correct non-standard residues are present, which is a mass and synthesis-record question. For tesamorelin, it has to establish that a full-length 44-mer is present rather than a truncated population, which is a chromatographic and mass question at a very different scale. Both are covered by the methods described in mass spectrometry peptide testing and HPLC peptide purity.
Choosing between them for a laboratory question
The two are not substitutes, and framing the choice as a ranking obscures what actually separates them. One is a small, synthetic, protease-resistant construct with a compact preclinical record that an investigator can reproduce and compare against. The other is a large, native-sequence analogue whose published record was generated in a setting a research-materials catalogue cannot speak to. The practical question is which of those situations matches the protocol being written.
- A question about selectivity across pituitary hormone outputs has a direct precedent with ipamorelin, where several analytes were measured in the same rat and pituitary-cell models (PMID 9849822).
- A question about a full-length releasing-factor analogue as a chemical entity, including its acyl modification, its synthesis and its purity profile, points to tesamorelin, since the fragment-based compounds cannot stand in for a 44-residue sequence.
- A question about protease-resistant peptide design is illustrated better by ipamorelin, whose D-residues, aminoisobutyric acid and C-terminal amide are textbook examples of the strategy in one short sequence.
- A question requiring a rodent baseline from the citations at hand can be built for ipamorelin and cannot be built for tesamorelin from these references alone.
Neither compound is presented here as an alternative to the other for any purpose beyond experimental design. They share a research area label and nothing else.
Storage and handling
Both arrive lyophilised. Sealed vials belong at minus 20 degrees Celsius or colder, dark and dry, and should be brought to room temperature before opening so that moisture does not condense onto the cake.
Tesamorelin merits the more conservative handling of the two. Its methionine is an oxidation target, so headspace air, repeated opening and prolonged room-temperature exposure in solution all deserve avoiding, and aliquoting immediately after reconstitution is the standard control. Its length also means that any hydrolysis event anywhere along the chain produces a fragment, so a lot held in solution drifts in composition rather than simply losing concentration.
Ipamorelin is the more robust molecule structurally but is not exempt from aqueous hydrolysis, and its small mass makes gravimetric error more consequential, so stock concentrations should be calculated from the weighed mass rather than assumed from the label. Diluent choice for either is discussed in the comparison of bacteriostatic water and sterile water, and lot documentation should be read against how to verify a peptide certificate of analysis, with current documents filed under certificates.
All compounds discussed are supplied strictly as laboratory research materials. They are not for human or veterinary use, and nothing here is medical advice.
References
Research use only